Press

PSYC Provides Shareholders with a Year-End Company Review for 2022

Dec 13 • 13 min read

PSYC Corporation (OTC Pink Market: PSYC), a multimedia leader focused on forward thinking market sectors such as psychedelics, cannabis, and mining and precious metals, is pleased to provide its shareholders with an overview of Company highlights and achievements from 2022 and insight into the potential it believes lies ahead in 2023. Incorporation and Launch of…

Filament Health to Present Live at VirtualInvestorConferences.com December 15th

Dec 13 • 2 min read

Filament Health (OTCQB:FLHLF | NEO:FH | FSE:7QS), a clinical stage natural psychedelic drug development company, today announced that Benjamin Lightburn, CEO and Co-Founder, will present live at VirtualInvestorConferences.com on December 15, 2022. Ben will provide details on Filament’s clinical trials studying natural psilocybin and psilocin, new revenue-driving supply partnerships, and recent patent issuances. DATE: December 15th, 2022TIME:…

Awakn Life Sciences’ Phase III Trial to Be Delivered in the UK National Health Service

Dec 13 • 4 min read

Awakn Life Sciences Corp. (NEO: AWKN | OTCQB: AWKNF | FSE: 954), a revenue-generating biotechnology company researching, developing, and commercializing therapeutics to treat addiction with a near-term focus on Alcohol Use Disorder (AUD), announces that its Phase III clinical trial exploring the use of ketamine-assisted therapy for the treatment of severe AUD will be delivered…

atai Life Sciences Strengthens Leadership Team with Appointment of Dr. Sahil V. Kirpekar as Chief Business Officer

Dec 13 • 3 min read

atai Life Sciences N.V., (NASDAQ: ATAI), a clinical stage biopharmaceutical company aiming to transform the treatment of mental health disorders, announced today its appointment of Dr. Kirpekar to serve as the Company’s Chief Business Officer, effective today. In this newly created role, Dr. Kirpekar will be responsible for atai’s pipeline strategy, building out its commercial…

PanGenomic Health Completes Acquisition of Mindleap Health

Dec 12 • 4 min read

PanGenomic Health Inc. CSE: NARA, is pleased to announce, further to its news releases dated September 1, 2022 and November 21, 2022, the completion of its previously announced acquisition (the “Transaction”) of Mindleap Health Inc. from Mydecine Innovations Group Inc., a company listed on the NEO Exchange. “We are excited about the acquisition of Mindleap as it represents…

Pages: 123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475767778798081828384858687888990919293949596979899100101102103104105106107108109110111112113114115116117118119120121122123124125126127128129130131132133134135136137138139140141142143144145146147148149150151152153154155156157158159160161162163164165166167168169170171172173174175176177178179180181182183184185186187188189190191192193194195196197198199200201202203204205206207208209210211212213214215216217218219220221222223224225226227228229230231232233234235236237238239240241242243244245246247248249250251252253254255256257258259260261262263264265266267268269270271272273274275276277278279280281282283284285286287288289290291292293294295296297298299300301302303304305306307308309310311312313314315316317318319320321322323324325326327328329330331332333334335336337338339340341342343344345346347348349350351352353354355356357358359360361362363364365366367368369370371372373374375376377378379380381382383384385386387388389390391392393394395396397398399400401402403404405406407408409410411412413414415416417418419420421422423424425426427428429430431432433434435